Angiotensin Converting Enzyme 2 News and Research

RSS

Two high blood pressure medicines effective in treating stable ischemic heart disease

Two medications commonly used to treat high blood pressure appear to be effective in treating a common type of heart disease known as stable ischemic heart disease, according to a new comparative effectiveness review funded by HHS' Agency for Healthcare Research and Quality.

20 Oct 2009

Boehringer Ingelheim Pharmaceuticals receives NDA approval from FDA for its Micardis Tablets 80 mg

Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) approved the supplemental New Drug Application (sNDA) for its angiotensin II receptor blocker (ARB) Micardis® (telmisartan) Tablets 80 mg for reduction of the risk of myocardial infarction, stroke, or death from cardiovascular causes in patients 55 years of age or older at high risk of developing major cardiovascular events who are unable to take angiotensin-converting enzyme (ACE) inhibitors.(1) MICARDIS is the most studied ARB in this high-risk patient population and has been commercially available to treat hypertension (high blood pressure) since its approval in 1998.

19 Oct 2009

Patients on statin drugs may have lower AAA surgery costs

Patients taking cholesterol-lowering statin drugs may have better results and lower procedure costs when having a common operation for repairing a bulging aorta, according to a new study presented at the 95th annual Clinical Congress of the American College of Surgeons.

15 Oct 2009

Diuretics effective as second-line agents in treating high blood pressure

A new review shows that diuretics — drugs often recommended as a first-line treatment for high blood pressure — are also effective when added as a second agent to other blood-pressure lowering drugs.

7 Oct 2009

ALL initiative three-year clinical observational study results published

A program that bundled two generic, low-cost drugs - a cholesterol-lowering statin and a blood pressure-lowering drug - and gave daily doses to 68,560 people with diabetes or heart disease for two years is estimated to have prevented 1,271 heart attacks and strokes in the first year following the study period, according to a Kaiser Permanente study published online in the American Journal of Managed Care.

3 Oct 2009

IMPROVE HF clinical trial results presented at annual HFSA meeting

Twenty-four month findings from IMPROVE HF, (The Registry to Improve the Use of Evidence-Based Heart Failure Therapies in the Outpatient Setting), funded by Medtronic, Inc., demonstrated that clinics using the process improvement program increased adherence to evidence-based, guideline-recommended care by 82 and 62 percent, respectively, for cardiac resynchronization therapy (CRT) and implantable cardioverter-defibrillator (ICD) use, and 80 percent for aldosterone antagonist use, all relative to baseline results.

15 Sep 2009

Modest decline for hypertension drug industry over the next decade

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that despite generic erosion of many branded agents -- most notably Novartis's Diovan -- the hypertension drug market will experience only modest decline over the next decade.

26 Aug 2009

Genetic mutation that helps regulate high blood pressure is a cause of inherited kidney disease

The discovery provides insight into a protein, renin, that is important in blood pressure regulation, and reveals the cause of one type of inherited kidney disease occurring in adults and children, said co-investigator Anthony Bleyer, M.D., professor of internal medicine-nephrology at the School of Medicine.

19 Aug 2009

ACE inhibitors and AT1R blockers suppress inflammation in mice

Conventional blood pressure medication can treat inflammation in an animal model mimicking multiple sclerosis (MS). This discovery was made by Dr. Michael Platten, head consultant at the department of Neurooncology at Heidelberg University Hospital and head of the Helmholtz Experimental Neuroimmunology Junior Research Group on at the German Cancer Research Center and his team in cooperation with scientists from Stanford University in California.

19 Aug 2009

Some blood pressure drugs may help protect against dementia, study shows

A particular class of medication used to treat high blood pressure could protect older adults against memory decline and other impairments in cognitive function, according to a newly published study from Wake Forest University School of Medicine.

23 Jul 2009

Diuretic drug works best at reducing risk of heart failure in hypertension

New research supports the findings of a landmark drug comparison study published in 2002 in which a diuretic drug or "water pill" outperformed other medications for high blood pressure. A scientific team including investigators from The University of Texas Health Science Center at Houston reports the findings in the May 11 issue of the Archives of Internal Medicine.

13 May 2009

Sinobiopharma announces Chinese approval of Perindopril

Sinobiopharma, Inc. has announced that it has received approval from the Chinese State Food and Drug Administration (SFDA) to manufacture and market its formulation of Perindopril, an anti-hypertension drug.

12 May 2009

Seniors with 1 type of heart failure may receive little or no benefit from drugs

People over 80 years of age suffering from a certain type of heart failure do not appear to benefit from most commonly prescribed heart medications, according to a study conducted at the Cedars-Sinai Heart Institute and published in the March 15 issue of The American Journal of Cardiology.

12 Mar 2009

Does gene show link between migraine and stroke or heart attacks?

New research looks at whether a gene variant may affect the link between migraine and stroke or heart attacks.

16 Feb 2009

The drug treatment of heart failure is influenced by the gender of the patient and of the physician

While the treatment of heart failure has improved over the past two decades, a new study reported in the European Journal of Heart Failure finds that "the use of evidence-based treatments appears to be imbalanced according to the gender of the patient".

23 Jan 2009

The drug treatment of heart failure is influenced by the gender of the patient and of the physician

21 Jan 2009

Generics as good as brand-name drugs when treating heart diseases

Contrary to the perception of some patients and physicians, there is no evidence that brand-name drugs are clinically superior to their generic counterparts, according to an article in the December 3 issue of JAMA, which examined studies comparing the effectiveness of generic vs. brand-name drugs for treating cardiovascular diseases.

3 Dec 2008

Diuretic reduces risk for type of heart failure that affects women more often than

New research by The University of Texas School of Public Health shows that a medication for high blood pressure called a diuretic or water pill is particularly effective at reducing the risk for a type of heart failure that affects women more often than men.

11 Nov 2008

The BEAUTIFUL study: Ivabradine and the reduction of cardiovascular events

The results of the much awaited BEAUTIFUL (morBidity-mortality EvAlUaTion of the If inhibitor ivabradine in patients with CAD and left ventricULar dysfunction) trial have shown that coronary artery disease (CAD) patients with left ventricular dysfunction (LVD) and a heart rate more than 70 bpm have a significantly higher risk of cardiovascular death and other cardiovascular events and in these patients (heart rate above 70 bpm) treatment with ivabradine further reduces the risk of the most important coronary events such as fatal and non-fatal myocardial infarction and coronary revascularisation by one third, even when these patients are already receiving optimal therapy.

31 Aug 2008

Global study shows Telmisartan reduces outcome of cardiovascular death, heart attack or stroke

An international study led by Canadian researchers has found that telmisartan, a medication used to lower blood pressure, reduced the outcome of cardiovascular death, heart attack or stroke in people who are unable to tolerate a widely available and effective standard treatment.

31 Aug 2008

Angiotensin Converting Enzyme 2 News and Research

Two high blood pressure medicines effective in treating stable ischemic heart disease

Boehringer Ingelheim Pharmaceuticals receives NDA approval from FDA for its Micardis Tablets 80 mg

Patients on statin drugs may have lower AAA surgery costs

Diuretics effective as second-line agents in treating high blood pressure

ALL initiative three-year clinical observational study results published

IMPROVE HF clinical trial results presented at annual HFSA meeting

Modest decline for hypertension drug industry over the next decade

Genetic mutation that helps regulate high blood pressure is a cause of inherited kidney disease

ACE inhibitors and AT1R blockers suppress inflammation in mice

Some blood pressure drugs may help protect against dementia, study shows

Diuretic drug works best at reducing risk of heart failure in hypertension

Sinobiopharma announces Chinese approval of Perindopril

Seniors with 1 type of heart failure may receive little or no benefit from drugs

Does gene show link between migraine and stroke or heart attacks?

The drug treatment of heart failure is influenced by the gender of the patient and of the physician

The drug treatment of heart failure is influenced by the gender of the patient and of the physician

Generics as good as brand-name drugs when treating heart diseases

Diuretic reduces risk for type of heart failure that affects women more often than

The BEAUTIFUL study: Ivabradine and the reduction of cardiovascular events

Global study shows Telmisartan reduces outcome of cardiovascular death, heart attack or stroke

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News